| Recruiting | A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizum NCT07010497 | Asan Medical Center | Phase 2 |
| Not Yet Recruiting | Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocell NCT07514455 | Ju Hyun Shim | Phase 2 |
| Not Yet Recruiting | Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial NCT07514429 | Ju Hyun Shim | Phase 2 |
| Not Yet Recruiting | Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addit NCT07298577 | Siriraj Hospital | N/A |
| Recruiting | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combinatio NCT07227012 | Pfizer | Phase 1 / Phase 2 |
| Not Yet Recruiting | Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB NCT07160361 | Second Affiliated Hospital of Xi'an Jiaotong University | Phase 4 |
| Not Yet Recruiting | Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the NCT06794073 | Shanghai Zhongshan Hospital | N/A |
| Recruiting | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid NCT06687941 | Aptamer Sciences, Inc. | Phase 1 |
| Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Into NCT06742892 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers NCT06422403 | National University Hospital, Singapore | Phase 2 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Recruiting | A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 NCT06349980 | Shanghai Henlius Biotech | Phase 2 |
| Not Yet Recruiting | Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma NCT06530784 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resecti NCT06454578 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma NCT06384950 | Taipei Veterans General Hospital, Taiwan | N/A |
| Not Yet Recruiting | Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS) NCT06060847 | Ospedale V. Fazzi | N/A |
| Recruiting | Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular NCT06365034 | Qianfoshan Hospital | — |
| Terminated | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcin NCT06302400 | Imperial College London | N/A |
| Unknown | A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. NCT06205732 | Qianfoshan Hospital | — |
| Recruiting | National Liver Cancer Screening Trial NCT06084234 | University of Texas Southwestern Medical Center | Phase 4 |
| Completed | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgical NCT05908786 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Not Yet Recruiting | Effects of Cognitive Intervention Therapy on Postoperative Delirium NCT06178939 | Yonsei University | N/A |
| Recruiting | Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI NCT05486572 | VA Office of Research and Development | N/A |
| Terminated | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 NCT04777851 | Translational Research in Oncology | Phase 3 |
| Recruiting | 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbum NCT05953961 | Ochsner Health System | N/A |
| Unknown | Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery NCT04962958 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC NCT05596630 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Completed | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA NCT05848947 | Sirtex Medical | Phase 4 |
| Recruiting | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy i NCT05870969 | Ruijin Hospital | — |
| Terminated | A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma NCT05653427 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinom NCT06629857 | Darul Sehat Hospital | — |
| Active Not Recruiting | Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma NCT05389527 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma NCT05580835 | University of Sao Paulo | N/A |
| Recruiting | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma NCT05366829 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Unknown | Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer NCT05383066 | Peking University First Hospital | — |
| Unknown | Possible Differences in HCC Course Depending on DAA Treatment NCT05376943 | Medical University of Warsaw | — |
| Completed | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer NCT05337137 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer NCT05540925 | Eastern Hepatobiliary Surgery Hospital | — |
| Completed | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumo NCT05091346 | Eisai Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Proce NCT04970212 | Techsomed Medical Technologies LTD | — |
| Terminated | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable fo NCT04732286 | Hoffmann-La Roche | Phase 3 |
| Completed | Assessment of the Impact of Acquisition Time, Respiratory Gating and New Qclear Reconstruction Modalities on t NCT04903340 | University Hospital, Bordeaux | — |
| Completed | A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable He NCT04763408 | Eisai Inc. | — |
| Completed | A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresecta NCT04297254 | Eisai Pharmaceuticals India Pvt. Ltd | Phase 4 |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Completed | HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT NCT04618367 | Sun Yat-sen University | N/A |
| Recruiting | A Study of PTX-9908 Injection for Non-resectable HCC with TACE NCT03812874 | TCM Biotech International Corp. | Phase 1 / Phase 2 |
| Unknown | TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) NCT04560751 | Zhejiang Cancer Hospital | — |
| Completed | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Pati NCT04487067 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonis NCT04338685 | Hoffmann-La Roche | Phase 1 |
| Completed | Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma NCT04310709 | Asan Medical Center | Phase 2 |
| Active Not Recruiting | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarteri NCT04246177 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepat NCT05352204 | Zhejiang University | — |
| Active Not Recruiting | Atezolizumab Plus Bevacizumab With HCC and HBV Infection NCT04180072 | National Health Research Institutes, Taiwan | N/A |
| Unknown | RFA Using Combined Bipolar and Monopolar Energy Deliver With Twin Cooled-Wet Electrodes NCT04331184 | Seoul National University Hospital | N/A |
| Unknown | RFA Using Gradual RF Energy Delivery Mode With Octopus Electrodes NCT04471272 | Seoul National University Hospital | N/A |
| Active Not Recruiting | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepat NCT04102098 | Hoffmann-La Roche | Phase 3 |
| Unknown | Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma NCT04803019 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 3 |
| Completed | CT Imaging for Guiding PA-TACE for HCC NCT06156748 | Zhujiang Hospital | — |
| Withdrawn | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma NCT02939807 | Medical University of South Carolina | Phase 2 |
| Recruiting | Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma NCT03894917 | The University of Texas Health Science Center at San Antonio | — |
| Unknown | Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT NCT04127396 | Beijing Ditan Hospital | Phase 4 |
| Recruiting | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma NCT03897543 | Abivax S.A. | Phase 1 / Phase 2 |
| Unknown | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients NCT04066543 | Zhejiang Cancer Hospital | Phase 2 |
| Active Not Recruiting | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor NCT04008797 | Eisai Inc. | Phase 1 / Phase 2 |
| Completed | Low-contrast Dose Liver CT Using Lean Body Weight Low Monoenergetic Images and Deep Learning-based Reconstruct NCT04027556 | Seoul National University Hospital | N/A |
| Completed | Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC NCT03939975 | Sun Yat-sen University | Phase 2 |
| Completed | A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants NCT05225207 | Eisai Korea Inc. | — |
| Active Not Recruiting | Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinom NCT03878550 | Glycotest, Inc. | — |
| Completed | A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma NCT04008082 | Eisai Co., Ltd. | — |
| Unknown | A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepat NCT03939845 | Shanghai Zhongshan Hospital | Phase 3 |
| Unknown | Randomized Control Trial (RCT) of Early Palliative Care for HCC NCT02556619 | The University of Texas Health Science Center, Houston | N/A |
| Completed | A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With U NCT03941873 | BeiGene | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatini NCT03713593 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma NCT03732547 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Terminated | A Study on the Angioarchitecture of Hepatocellular Carcinoma NCT03808766 | Chinese University of Hong Kong | N/A |
| Terminated | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipio NCT03727633 | University Hospital, Montpellier | Phase 2 |
| Unknown | Prospective Surveillance for Very Early Hepatocellular Carcinoma NCT03588442 | Eastern Hepatobiliary Surgery Hospital | — |
| Terminated | Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma NCT03662841 | Chinese University of Hong Kong | N/A |
| Completed | A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresecta NCT03663114 | Eisai Inc. | — |
| Completed | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC NCT03347292 | Bayer | Phase 1 |
| Completed | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular NCT03572582 | AIO-Studien-gGmbH | Phase 2 |
| Withdrawn | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic NCT03636607 | Fifth Affiliated Hospital, Sun Yat-Sen University | N/A |
| Completed | Safety and Efficacy of "Immuncell-LC" in TACE Therapy NCT02856815 | GC Cell Corporation | Phase 2 |
| Unknown | Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver NCT03766555 | Chinese University of Hong Kong | N/A |
| Terminated | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of NCT03433703 | Eisai Inc. | Phase 2 |
| Completed | Harms of Hepatocellular Carcinoma Surveillance NCT03756051 | University of Texas Southwestern Medical Center | — |
| Completed | Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5 NCT02582918 | University of Texas Southwestern Medical Center | N/A |
| Completed | Study to Evaluate VORTX Rx (Theresa) NCT03741088 | HistoSonics, Inc. | N/A |
| Completed | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Loc NCT03434379 | Hoffmann-La Roche | Phase 3 |
| Completed | Effect of DAAs on Behavior of HCC in HCV Patients NCT03200171 | Al-Azhar University | — |
| Completed | A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Sing NCT05038397 | MedicalExcellence | N/A |
| Completed | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma NCT03418922 | Eisai Co., Ltd. | Phase 1 |
| Completed | Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma NCT03586050 | Ethicon, Inc. | N/A |
| Terminated | TATE Versus TACE in Intermediate Stage HCC NCT03145558 | Teclison Ltd. | Phase 2 |
| Completed | Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment NCT03389126 | Seoul National University Hospital | Phase 2 |
| Completed | Meclizine for Hepatocellular Carcinoma NCT03253289 | Tannaz Armaghnay | Phase 1 |
| Completed | A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) NCT03289533 | Pfizer | Phase 1 |
| Active Not Recruiting | Paediatric Hepatic International Tumour Trial NCT03017326 | University of Birmingham | Phase 3 |
| Unknown | Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection NCT03261791 | Shanghai Zhongshan Hospital | Phase 2 |
| Completed | Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies NCT03291379 | Boston Scientific Corporation | EARLY_Phase 1 |
| Withdrawn | Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Loca NCT03168152 | University of Michigan Rogel Cancer Center | N/A |
| Completed | Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previou NCT03062358 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) NCT03130712 | Shanghai GeneChem Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as NCT02847468 | Centre Georges Francois Leclerc | N/A |
| Unknown | Needle Guiding Robot for Radiofrequency Ablation: Safety and Efficacy Study on Hepatocellular Carcinoma Patien NCT03005756 | Asan Medical Center | N/A |
| Completed | Circulating Tumor Cells and Tumor DNA in HCC and NET NCT02973204 | University of Aarhus | — |
| Completed | RFA for Small HCC With No-touch Technique Using Octopus Electrode NCT02832882 | Seoul National University Hospital | N/A |
| Terminated | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib NCT03008512 | Gachon University Gil Medical Center | Phase 2 |
| Unknown | Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients NCT02813096 | Guangxi Medical University | N/A |
| Completed | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellul NCT02859324 | Celgene | Phase 1 / Phase 2 |
| Unknown | Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumo NCT03191123 | Huazhong University of Science and Technology | N/A |
| Unknown | Dynamic Contrast Enhanced HCC SABR Liver Study NCT02847767 | British Columbia Cancer Agency | N/A |
| Unknown | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy NCT02959151 | Shanghai GeneChem Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode NCT02806076 | Seoul National University Hospital | N/A |
| Completed | DCE-MRI for Assessment of Response to TACE of HCC NCT02878109 | Centre hospitalier de l'Université de Montréal (CHUM) | — |
| Not Yet Recruiting | Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma NCT02779465 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Completed | A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to De NCT02564614 | Hoffmann-La Roche | Phase 1 |
| Unknown | HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC NCT03020342 | National Taiwan University Hospital | — |
| Completed | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HC NCT02716766 | The University of Hong Kong | Phase 2 |
| Unknown | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC NCT02715362 | Shanghai GeneChem Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer NCT02644603 | Shanghai Zhongshan Hospital | N/A |
| Unknown | Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With NCT02338297 | Nanjing Medical University | Phase 3 |
| Unknown | Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection NCT02738697 | Sun Yat-sen University | Phase 3 |
| Unknown | Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma NCT02640924 | Chang Gung Memorial Hospital | Phase 3 |
| Unknown | TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carci NCT02630108 | Shanghai Zhongshan Hospital | Phase 3 |
| Unknown | Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation NCT02631499 | Fudan University | Phase 4 |
| Completed | Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study NCT02635347 | Rutgers, The State University of New Jersey | N/A |
| Terminated | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma NCT01171482 | Seoul National University Hospital | Phase 2 |
| Withdrawn | Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer NCT02304445 | Juan Sanabria, MD | N/A |
| Terminated | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response NCT02439008 | Centre Oscar Lambret | N/A |
| Completed | Fingerprint Characterization of Advanced HCC NCT02372162 | University Hospital Tuebingen | — |
| Unknown | MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma NCT02448056 | National Taiwan University Hospital | — |
| Completed | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Particip NCT02421185 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Unknown | HR Versus RFA for HCC in Patients With PHT NCT02192671 | Guangxi Medical University | Phase 3 |
| Terminated | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer NCT02323906 | Celgene | Phase 1 |
| Unknown | Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Lo NCT02308319 | Samsung Medical Center | Phase 4 |
| Completed | RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System NCT02312817 | University of Texas Southwestern Medical Center | N/A |
| Withdrawn | Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma) NCT01669668 | Washington University School of Medicine | Phase 2 |
| Unknown | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer NCT02794337 | Tata Memorial Hospital | Phase 2 / Phase 3 |
| Unknown | Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Pati NCT02580929 | Peking Union Medical College | N/A |
| Unknown | Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Car NCT02293850 | Oncolys BioPharma Inc | Phase 1 |
| Active Not Recruiting | SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE NCT02221778 | University of Sao Paulo | Phase 2 |
| Completed | Hepatocellular Carcinoma and Rheumatoid Arthritis NCT02880306 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | — |
| Completed | c-Met Second-Line Hepatocellular Carcinoma NCT02115373 | Merck KGaA, Darmstadt, Germany | Phase 1 / Phase 2 |
| Completed | A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer NCT02069041 | Eli Lilly and Company | Phase 1 |
| Recruiting | Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma NCT06571396 | Qilu Hospital of Shandong University | — |
| Unknown | Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity NCT02148562 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) NCT02329860 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Enrolling By Invitation | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer NCT02081755 | Baylor Research Institute | Phase 4 |
| Completed | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma NCT01988493 | Merck KGaA, Darmstadt, Germany | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC NCT02018757 | First Hospital of China Medical University | Phase 2 |
| Completed | Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Ea NCT01933945 | Bayer | — |
| Unknown | Circulating Tumor Cells for Hepatocellular Carcinoma NCT01930383 | National Taiwan University Hospital | — |
| Terminated | A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody Wit NCT01911273 | Pfizer | Phase 2 |
| Completed | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) NCT01915602 | Bayer | Phase 2 |
| Completed | Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) NCT01915589 | Bayer | Phase 2 |
| Completed | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Soraf NCT01897038 | Hoffmann-La Roche | Phase 1 |
| Unknown | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma NCT02403544 | Chinese Academy of Medical Sciences | Phase 1 |
| Completed | Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolizati NCT01911000 | Samsung Medical Center | Phase 2 |
| Completed | Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nex NCT01908322 | Bayer | — |
| Completed | Sorafenib for Residue Disease After Resection With Curative Intent NCT01751763 | Bayer | — |
| Completed | A Study of rSIFN-co in Subjects With Advanced Solid Tumors NCT02387307 | Sichuan Huiyang Life Science and Technology Corporation | Phase 1 |
| Unknown | Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma NCT01861912 | Guangdong Provincial People's Hospital | Phase 2 / Phase 3 |
| Completed | Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular NCT01839630 | Bayer | — |
| Completed | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma NCT01774344 | Bayer | Phase 3 |
| Unknown | Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis NCT03083002 | University of Modena and Reggio Emilia | — |
| Completed | Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests NCT01790633 | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | N/A |
| Unknown | Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase NCT01715532 | Fudan University | Phase 2 |
| Unknown | TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma NCT01605734 | Shandong Cancer Hospital and Institute | Phase 2 |
| Completed | Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolizatio NCT02848638 | University of Washington | — |
| Completed | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma NCT01655693 | Valerio Therapeutics | Phase 3 |
| Unknown | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate He NCT01556815 | Shandong Cancer Hospital and Institute | Phase 2 |
| Completed | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma NCT01594125 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma NCT01507168 | Hoffmann-La Roche | Phase 2 |
| Completed | Application of HBV Rapid Tests as a Tool for Wide-Use Screening NCT01767597 | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | N/A |
| Completed | Advanced Image Guidance Utilized in Liver Surgery NCT01666145 | Wake Forest University Health Sciences | N/A |
| Withdrawn | Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Live NCT01501240 | Jae Ho Byun | — |
| Withdrawn | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. NCT01441388 | Pfizer | Phase 1 |
| Completed | Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular NCT01490203 | Seoul National University Hospital | — |
| Terminated | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma NCT01425996 | Taiwan Liposome Company | Phase 1 / Phase 2 |
| Completed | HCC Response Assessment by MRI After SBRT NCT03088423 | Institut de Cancérologie de Lorraine | — |
| Unknown | 3T MRI to Predict TACE Response of HCC NCT02070822 | National Taiwan University Hospital | — |
| Completed | TRC105 for Liver Cancer That Has Not Responded to Sorafenib NCT01375569 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease NCT01355107 | University Hospital Freiburg | — |
| Completed | A Study of LY2157299 in Participants With Hepatocellular Carcinoma NCT01246986 | Eli Lilly and Company | Phase 2 |
| Unknown | Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas NCT01393093 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Unknown | Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas NCT01393197 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Completed | A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellula NCT01308723 | Hoffmann-La Roche | Phase 1 |
| Completed | Sorafenib and TRC105 in Hepatocellular Cancer NCT01306058 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma NCT01258608 | Human Genome Sciences Inc., a GSK Company | Phase 1 / Phase 2 |
| Withdrawn | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma NCT01327521 | Albert Koong | Phase 3 |
| Completed | Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging NCT01387503 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | N/A |
| Completed | Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. NCT01204177 | Bayer | Phase 2 |
| Withdrawn | GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study NCT01191385 | Bayer | — |
| Completed | Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants NCT02366286 | Mayo Clinic | — |
| Unknown | Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib NCT01217034 | Kindai University | Phase 2 |
| Unknown | Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC NCT01214343 | Ministry of Health, Labour and Welfare, Japan | Phase 3 |
| Terminated | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria NCT01141478 | Loma Linda University | N/A |
| Terminated | Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) NCT01337492 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer NCT01310062 | Ministry of Health, Malaysia | — |
| Terminated | Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in As NCT01108705 | Bristol-Myers Squibb | Phase 3 |
| Completed | Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) NCT01078415 | Angiodynamics, Inc. | N/A |
| Terminated | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) NCT01009593 | Abbott | Phase 3 |
| Unknown | Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Ci NCT01201655 | Xijing Hospital | — |
| Completed | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma NCT01668134 | Washington University School of Medicine | Phase 1 |
| Completed | Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas NCT01040559 | Centre Hospitalier Universitaire Dijon | Phase 1 |
| Completed | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellul NCT01004003 | Boehringer Ingelheim | Phase 2 |
| Completed | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients NCT00987935 | Boehringer Ingelheim | Phase 2 |
| Completed | Regulatory Post Marketing Surveillance Study on Nexavar® NCT01012011 | Bayer | — |
| Terminated | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma NCT01020812 | Stanford University | Phase 1 / Phase 2 |
| Completed | Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma NCT01003015 | Bayer | Phase 2 |
| Completed | Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer NCT00920192 | GlaxoSmithKline | Phase 1 |
| Completed | A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinom NCT01171651 | Jennerex Biotherapeutics | Phase 2 |
| Completed | A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area NCT00913757 | National Cancer Institute (NCI) | — |
| Completed | Adjuvant TACE to Reduce the HCC Recurrence After Resection NCT02788526 | Sun Yat-sen University | Phase 3 |
| Completed | Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable He NCT00919009 | National Cancer Center, Korea | Phase 2 |
| Completed | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcino NCT00901901 | Bayer | Phase 3 |
| Completed | Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan NCT01411436 | Bayer | — |
| Completed | Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance NCT00926536 | Stanford University | N/A |
| Completed | A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Tran NCT00855218 | Bayer | Phase 2 |
| Unknown | Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma NCT00843934 | Nihon University | Phase 2 / Phase 3 |
| Completed | Proteomic Analysis of Human Hepatocellular Carcinoma NCT01177631 | Far Eastern Memorial Hospital | N/A |
| Completed | Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma NCT00827723 | University of Lausanne Hospitals | — |
| Completed | Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma NCT00857805 | Loma Linda University | N/A |
| Completed | Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma NCT01096914 | Cardarelli Hospital | N/A |
| Completed | Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib NCT00812175 | Bayer | — |
| Completed | Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepat NCT04172194 | Centre Hospitalier Universitaire de Nice | — |
| Completed | CIK Treatment for HCC Patient Underwent Radical Resection NCT01749865 | Sun Yat-sen University | Phase 3 |
| Completed | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) NCT00692770 | Bayer | Phase 3 |
| Completed | A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma NCT00554372 | Jennerex Biotherapeutics | Phase 2 |
| Terminated | Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector NCT00763776 | Assistance Publique - Hôpitaux de Paris | N/A |
| Terminated | Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer NCT00699374 | Pfizer | Phase 3 |
| Unknown | 11C-Acetate PET/CT Non-FDG-Avid Tumors NCT00687778 | Tel-Aviv Sourasky Medical Center | — |
| Completed | INSIGHT - Post Marketing Surveillance NCT00792350 | Bayer | — |
| Completed | Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE NCT00936689 | Rita Golfieri | Phase 4 |
| Unknown | Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors NCT00610389 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 |
| Completed | Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinom NCT00703365 | Mahidol University | Phase 2 |
| Terminated | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC NCT00576056 | University of Pittsburgh | Phase 2 |
| Completed | Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma NCT00559455 | Sanofi | Phase 2 |
| Terminated | SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma NCT00503867 | Sirtex Medical | N/A |
| Completed | A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction NCT00437424 | Bristol-Myers Squibb | Phase 1 |
| Completed | Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular C NCT00508001 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients NCT00470340 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) NCT00490685 | Istituto Clinico Humanitas | Phase 2 |
| Completed | Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in A NCT00471965 | Sanofi | Phase 3 |
| Terminated | A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma NCT00440934 | Pasche, Boris, M.D. | Phase 2 |
| Completed | Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma NCT00662246 | National Cancer Center, Korea | Phase 1 |
| Completed | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer NCT00370513 | GlaxoSmithKline | Phase 1 |
| Completed | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors NCT00493883 | Southwestern Regional Medical Center | Phase 1 / Phase 2 |
| Completed | Use of N-Acetylcysteine During Liver Procurement NCT01394497 | Azienda Ospedaliera di Padova | Phase 2 |
| Completed | A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma. NCT00444782 | Pharmexa A/S | Phase 2 |
| Unknown | A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatoc NCT00384800 | Far Eastern Memorial Hospital | Phase 2 |
| Completed | Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcin NCT00464295 | Aga Khan University | Phase 2 |
| Completed | A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma NCT00355355 | Light Sciences Oncology | Phase 3 |
| Completed | Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Me NCT00392366 | BioTex, Inc. | N/A |
| Completed | Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcath NCT00494299 | Bayer | Phase 3 |
| Completed | A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular C NCT00492752 | Bayer | Phase 3 |
| Completed | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis NCT00116454 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Terminated | A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma NCT02482909 | Seoul National University Hospital | N/A |
| Unknown | Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells NCT00327496 | Mackay Memorial Hospital | N/A |
| Completed | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma NCT00108953 | Bayer | Phase 2 |
| Completed | Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma NCT00122876 | Light Sciences Oncology | Phase 1 / Phase 2 |
| Completed | A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma NCT00105443 | Bayer | Phase 3 |
| Completed | A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Adva NCT02576964 | Hoffmann-La Roche | Phase 2 |
| Completed | The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinom NCT00397540 | Seoul National University Hospital | N/A |
| Terminated | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver NCT00582400 | The University of Texas Medical Branch, Galveston | Phase 2 |
| Unknown | Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Ca NCT00155103 | National Taiwan University Hospital | — |
| Completed | Oxaliplatin in Unresectable Hepatocellular Carcinoma NCT00280618 | Sanofi | Phase 2 |
| Completed | PI-88 in Hepatocellular Carcinoma After Hepatectomy NCT00247728 | Cellxpert Biotechnology Corp. | Phase 2 |
| Completed | Dose Escalation Study for Primary Hepatocellular Carcinoma NCT00243841 | Indiana University School of Medicine | N/A |
| Terminated | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care NCT00081900 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Unknown | A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arter NCT00563095 | Hospital Authority, Hong Kong | N/A |
| Completed | Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation NCT00080236 | Conatus Pharmaceuticals Inc. | Phase 2 |
| Terminated | Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve NCT00225290 | TTY Biopharm | Phase 3 |
| Completed | TK-based Suicide Gene Therapy for Hepatocellular Carcinoma NCT00844623 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 1 |
| Completed | Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellu NCT00635323 | Pfizer | Phase 2 |
| Completed | Testing of ADI-PEG in Hepatocellular Carcinoma NCT00056992 | FDA Office of Orphan Products Development | Phase 2 |
| Completed | A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma NCT00044512 | Bayer | Phase 2 |
| Completed | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Prolif NCT00759109 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer NCT00034333 | FeRx | Phase 2 / Phase 3 |
| Completed | A National Registry of Patients With Hepatocellular Carcinoma NCT00178867 | Vanderbilt University | — |
| Completed | Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer NCT01034865 | Stanford University | — |
| Terminated | Comparison Between Radiofrequency Versus Ethanol Injection for the Treatment of Hepatocellular Carcinoma NCT00355212 | Azienda Ospedaliera San Giovanni Battista | Phase 3 |
| Unknown | Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) V NCT00121914 | Medical University of Vienna | Phase 3 |
| Completed | Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma NCT00386984 | University Hospital Freiburg | Phase 3 |
| Completed | A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma NCT00082082 | SciClone Pharmaceuticals | Phase 2 |
| Withdrawn | Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion NCT01722175 | Washington University School of Medicine | Phase 2 |
| No Longer Available | Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer NCT00701168 | Leo W. Jenkins Cancer Center | — |
| Completed | Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate NCT00006332 | National Center for Research Resources (NCRR) | Phase 2 |
| Completed | East-West Hepatocellular Carcinoma Study Group NCT01237132 | University of Milan | — |